Korea Science Journalists Association and National Institute of Health Host Media Academy

Goal: Establishment of a 'Vaccine Library' for Pandemic Preparedness

Targeting Phase 1 Clinical Trials for Vaccine by 2029... Parallel Development of Treatments

In response to the Nipah virus, which can have a fatality rate as high as 75%, the government is simultaneously advancing the development of both vaccines and treatments. Through these research efforts, the government aims to establish a "vaccine library" and a foundation for therapeutic development, enabling rapid response in the event of future pandemics.


Wooinok, Senior Health Researcher in the Vaccine Research and Development Division at the Public Vaccine Development Support Center, explained at the media academy held on the 17th at HJ Business Center in Jongno-gu, Seoul, "Nipah virus is a high-risk infectious disease with a fatality rate ranging from 40% to 75%, yet there are no commercialized vaccines or treatments available so far. Proactive vaccine development is necessary as a measure to prepare for pandemics."


Woo Inok, Senior Researcher of Vaccine Research and Development Division at the Public Vaccine Development Support Center, is explaining the current status of Nipah virus vaccine development at the Media Academy held on the 17th at the HJ Business Center in Jongno-gu, Seoul. Photo by the Korea Science Journalists Association

Woo Inok, Senior Researcher of Vaccine Research and Development Division at the Public Vaccine Development Support Center, is explaining the current status of Nipah virus vaccine development at the Media Academy held on the 17th at the HJ Business Center in Jongno-gu, Seoul. Photo by the Korea Science Journalists Association

View original image

The key to vaccine development lies in designing structures that closely resemble the virus. On the surface of the Nipah virus are two essential proteins: the G protein and the F protein. The G protein allows the virus to attach to human cell receptors, while the F protein facilitates viral entry into cells by inducing fusion with the cell membrane. Researchers are designing vaccines by creating antigens that mimic these two proteins, allowing the immune system to recognize the virus in advance.


Currently, Nipah virus vaccine development has progressed beyond the discovery of candidate substances to the stage of demonstrating efficacy in preclinical studies. Since 2022, the National Institute of Health has identified candidate antigens and confirmed their immunogenicity in animal models. In partnership with domestic companies, efforts are underway to simultaneously develop vaccines based on recombinant protein and messenger ribonucleic acid (mRNA) platforms.


The research team is also optimizing antigen structures using artificial intelligence (AI). Researcher Woo stated, "Recombinant proteins in their natural state are often structurally unstable. By leveraging AI to design more stable structures, we can induce a stronger immune response." She added, "As such data accumulates, we will be able to significantly shorten vaccine development timelines when new infectious diseases emerge in the future."


This year, the team will begin efficacy evaluations using a ferret model and establish a GMP manufacturing process. Following toxicity and safety assessments, the goal is to enter Phase 1 clinical trials by 2029. Ultimately, the aim is to accumulate candidate substances and related data up to the clinical stage in the form of a 'vaccine library,' thereby establishing a system capable of developing a vaccine within 100 days in the event a new, similar virus emerges.

Hyunju Kim, Health Research Officer of the Emerging Virus and Vector Research Division at the National Institute of Health, is explaining the status of Nipah virus therapeutic development at the media academy held on the 17th at the HJ Business Center in Jongno-gu, Seoul. The Korea Science Journalists Association

Hyunju Kim, Health Research Officer of the Emerging Virus and Vector Research Division at the National Institute of Health, is explaining the status of Nipah virus therapeutic development at the media academy held on the 17th at the HJ Business Center in Jongno-gu, Seoul. The Korea Science Journalists Association

View original image

Treatment development is being pursued in parallel with vaccine development. Efforts are underway to develop both antibody therapies and antiviral drugs. The antibody therapy is being developed in the form of a bispecific antibody that combines antibodies targeting the G and F proteins of the virus, aiming to block multiple stages of infection simultaneously. The antiviral approach focuses on inhibiting viral replication inside cells by targeting enzymes involved in RNA replication.


Kim Hyunju, Health Research Officer of the Emerging Virus and Vector Research Division at the National Institute of Health, stated, "We have secured three types of neutralizing antibodies targeting the G protein and are developing additional antibodies targeting the F protein using alpaca-derived 'nanobody' technology. Nanobodies are about one-tenth the size of conventional antibodies, allowing them to access the virus more easily and be combined to enhance their function."



Nam Jaehwan, Director of the National Institute of Health, said, "Although the Nipah virus is not a respiratory infectious disease, given its zoonotic nature, there is always the possibility that it could evolve to become more transmissible among humans. We will continue to expand collaboration with domestic and international research institutions to secure vaccines and response technologies to address future infectious disease threats."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing